CEEOR · Medical devices

From device classification to reimbursement, without dead ends

We guide manufacturers, importers and distributors through MDR and IVDR compliance and through the reimbursement systems of Czechia and Slovakia — technical documentation, clinical evidence, EUDAMED registration and market access, handled by one team.

Operating since 2006Czechia, Slovakia and CEERegulatory and health economics under one roof

How we work

Five steps we repeat on every project

The sequence stays the same for a single device and for a portfolio of hundreds. What changes is depth, not logic.

A common finding at intake

In roughly half of our projects the device turns out to have a different reimbursement pathway than assumed. Reworking a dossier is cheaper than a failed procedure.

  1. 01

    Intake and regulatory strategy

    Qualification, classification, the applicable conformity assessment route and a map of reimbursement pathways in Czechia and Slovakia.

  2. 02

    Plan and timeline

    Concrete steps with deadlines, owners and effort estimates — including the points where a notified body, SÚKL or a medical society has to be involved.

  3. 03

    Documentation and data

    Technical documentation, clinical evaluation, literature review, health-economic model and budget impact analysis, in the form the reviewer expects.

  4. 04

    Submission and negotiation

    We file, defend and answer questions — with SÚKL, insurance funds, notified bodies and medical societies.

  5. 05

    Life after market entry

    Post-market surveillance, PMCF and PMPF, trend reporting, reimbursement maintenance and legislative monitoring.

Run documentation and reimbursement yourself — in MedaSet

MedaSet is our cloud application for medical device documentation. It walks you through CE and SÚKL documentation, reimbursement applications, budget impact modelling and EUDAMED XML output — with versioning, notifications and quality control.

  • One place — technical documentation, reimbursement and clinical data
  • Versions and alerts — no more hunting for the approved revision
  • EUDAMED XML — no manual re-typing between systems
  • Company-wide access — QA, RA, marketing and sales in one logic
  • Three support levels — from self-service to full outsourcing

Why CEEOR

Science, practice and analytics in one place

CEEOR was founded in 2006 as a research company supporting health innovation for patients. We have been in health data and reimbursement ever since — first in pharma, today equally in med-tech.

Our team combines experience from the regulator and from industry. That is a practical difference: we know not only what the rules require, but how they are assessed.

More about us

2006Year the company was founded
20+years in health data and reimbursement
CZ · SKhome markets, plus the CEE region
Dozensof successful submissions and negotiations

FAQ

What clients ask first

We are a non-EU manufacturer. What do we need to enter the Czech and Slovak market?

An EU authorised representative, technical documentation compliant with MDR or IVDR, Czech (and Slovak) language versions of the labelling and instructions for use, actor and device registration in EUDAMED with a valid SRN, and — for most classes — a notified body certificate.

Reimbursement is a separate track with its own evidence requirements. Starting it after certification is the single most common cause of delay we see.

How different is Czech reimbursement from other EU markets?

The mechanics are country-specific. Devices used inside a healthcare facility are usually billed as separately billed material (ZUM) alongside a procedure; devices prescribed to patients follow a categorisation tree with defined reimbursement groups under Act No. 48/1997 Coll.

What travels well from other markets is the evidence: a solid budget impact model and comparative clinical data can be adapted. What does not travel is the pathway logic.

Do you work in Slovakia and the wider CEE region?

Czechia and Slovakia are our home markets — in Slovakia we prepare pharmacoeconomic analyses and MER. Through our network we also cover further Central and Eastern European markets; the exact scope is confirmed at project start.

Can you take over a project that is already under way?

Yes. A frequent starting point is a gap review of existing technical documentation or a stalled reimbursement dossier. We tell you what is missing, what is inconsistent and in what order to fix it.

Have a device and no clear route?

Tell us what the device is and where you are. We will come back with a first read on classification, reimbursement pathway and the nearest deadlines.

Managing DirectorMartin Kolekmartin.kolek@ceeor.com+420 728 411 042
Regulatory AffairsIvana Kubátováivana.kubatova@ceeor.com+420 602 345 190